|
Name |
1-Nonadecanol
|
| Molecular Formula | C19H40O | |
| IUPAC Name* |
nonadecan-1-ol
|
|
| SMILES |
CCCCCCCCCCCCCCCCCCCO
|
|
| InChI |
InChI=1S/C19H40O/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20/h20H,2-19H2,1H3
|
|
| InChIKey |
XGFDHKJUZCCPKQ-UHFFFAOYSA-N
|
|
| Synonyms |
1-NONADECANOL; 1454-84-8; Nonadecan-1-ol; NONADECANOL; Nonadecyl alcohol; A465X576KO; UNII-A465X576KO; n-Nonadecanol-1; n-nonadecyl alcohol; EINECS 215-930-4; MFCD00002824; 1-Nonadecanol, 99%; AI3-36471; SCHEMBL103937; AMY5925; DTXSID90870875; ZINC43504481; AKOS015839822; CS-W004297; HY-W004297; AS-10300; FT-0608161; N0284; H10890; J-008118; Q27273608; 1-Nonadecanol, European Pharmacopoeia (EP) Reference Standard
|
|
| CAS | 1454-84-8 | |
| PubChem CID | 80281 | |
| ChEMBL ID | NA |
Chemical Classification: |
|
|
|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference | |
|---|---|---|---|---|---|---|---|---|
| Endophyte ID | Endophyte Name | Family | Genus | Taxonomy ID | GenBank ID | Closest GenBank ID | Reference |
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Bioactivity Name | Target ID | Target Name | Target Type | Target Organism | Target Organism ID | Potency of Bioactivity | Activity Type | Value | Unit | Endophyte ID | Endophyte Name |
| Molecular Weight: | 284.5 | ALogp: | 8.9 |
| HBD: | 1 | HBA: | 1 |
| Rotatable Bonds: | 17 | Lipinski's rule of five: | Rejected |
| Polar Surface Area: | 20.2 | Aromatic Rings: | 0 |
| Heavy Atoms: | 20 | QED Weighted: | 0.299 |
| Caco-2 Permeability: | -4.878 | MDCK Permeability: | 0.00001160 |
| Pgp-inhibitor: | 0 | Pgp-substrate: | 0.001 |
| Human Intestinal Absorption (HIA): | 0.004 | 20% Bioavailability (F20%): | 0.11 |
| 30% Bioavailability (F30%): | 0.996 |
| Blood-Brain-Barrier Penetration (BBB): | 0.043 | Plasma Protein Binding (PPB): | 97.61% |
| Volume Distribution (VD): | 3.195 | Fu: | 1.48% |
| CYP1A2-inhibitor: | 0.179 | CYP1A2-substrate: | 0.178 |
| CYP2C19-inhibitor: | 0.276 | CYP2C19-substrate: | 0.052 |
| CYP2C9-inhibitor: | 0.085 | CYP2C9-substrate: | 0.95 |
| CYP2D6-inhibitor: | 0.049 | CYP2D6-substrate: | 0.036 |
| CYP3A4-inhibitor: | 0.169 | CYP3A4-substrate: | 0.031 |
| Clearance (CL): | 5.338 | Half-life (T1/2): | 0.087 |
| hERG Blockers: | 0.287 | Human Hepatotoxicity (H-HT): | 0.01 |
| Drug-inuced Liver Injury (DILI): | 0.081 | AMES Toxicity: | 0.006 |
| Rat Oral Acute Toxicity: | 0.015 | Maximum Recommended Daily Dose: | 0.014 |
| Skin Sensitization: | 0.962 | Carcinogencity: | 0.034 |
| Eye Corrosion: | 0.994 | Eye Irritation: | 0.923 |
| Respiratory Toxicity: | 0.488 |
| Similar NPs | Similar Drugs | ||||||
|---|---|---|---|---|---|---|---|
| NPs ID | NPs 2D Structure | Similarity Score | TTD ID | Drug 2D Structure | Similarity Score | ||
| ENC000431 | ![]() |
0.951 | D00AOJ | ![]() |
0.866 | ||
| ENC000284 | ![]() |
0.948 | D07ILQ | ![]() |
0.639 | ||
| ENC000761 | ![]() |
0.906 | D00FGR | ![]() |
0.529 | ||
| ENC000486 | ![]() |
0.897 | D0Z5SM | ![]() |
0.514 | ||
| ENC000449 | ![]() |
0.866 | D0O1PH | ![]() |
0.476 | ||
| ENC000082 | ![]() |
0.845 | D00STJ | ![]() |
0.470 | ||
| ENC000285 | ![]() |
0.841 | D05ATI | ![]() |
0.438 | ||
| ENC000357 | ![]() |
0.806 | D0T9TJ | ![]() |
0.345 | ||
| ENC000430 | ![]() |
0.803 | D0P1RL | ![]() |
0.344 | ||
| ENC000723 | ![]() |
0.803 | D0MM8N | ![]() |
0.319 | ||